Why we just raised €1M, and what we're building.

We’ve closed our €1 million pre-seed round.

The round was led by Maia Ventures (Praesidium SA), through the "Maia I" fund, in which the European Investment Fund (EIF) participates under the InvestEU Fund programme. Other participants in the round include a sector business angel, PM Holding, and Terra Next, the acceleration programme dedicated to innovative startups and SMEs in the bioeconomy sector, an initiative of CDP Venture Capital with the participation of Intesa Sanpaolo Innovation Center and Cariplo Factory.
We're thankful to all of them. They didn’t just see a product — they saw the potential to reshape entire industries with our technology.
Here’s the story behind the funding and where we’re headed next.

The Problem

Despite incredible advances in DNA sequencing, the analysis part is still stuck in the past.
Bioinformaticians spend weeks processing data that should take days.
The traditional approach compares every sample to a single “reference genome” — like trying to understand an entire city by comparing everyone to one person. It’s limiting and often misses the variations that matter most.
We knew there had to be a better way.

Our Solution: Pangenomics

Instead of relying on a single reference genome, we use pangenome graphs that capture genetic variation across many individuals or species.
That’s where GenoGra operates. Our team has built a platform that turns complex pangenomic analysis into something not only technically advanced, but also usable and scalable for organizations conducting population-level studies.
What used to be a complex, time-consuming process can now become a streamlined workflow — unlocking insights from DNA at an entirely new scale.

Why Non-Human First?

Our initial launch will focus on areas outside human health — fields where genomics can be game-changing.
GenoGra sees big opportunities in sectors like agriculture and food, animal breeding, livestock health, energy production, and industrial microbiology. These domains are full of potential. By starting here, we aim to fill that gap and bring cutting-edge DNA analysis to the industries that need it most.

What’s Next

This funding enables us to run three tracks in parallel as we enter our next chapter:

• From pilot to production
  We’re moving our existing pilot projects into fully production-ready solutions for our early partners and customers.

• Laying the human groundwork
  In the background, we’ll begin building the foundation for human genomics applications. While our focus is non-human for now, we’re preparing to expand into clinical genomics when the time is right.

• Growing the team
  Innovation requires talent. We plan to expand our team throughout 2026 so we can take on new challenges and scale into new markets.